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Neuroblastoma (NB) is the most common extracranial solid tu-
mor during childhood. The amplification of the MYCN oncogene
(MYCNamp) was found in about 25% of NB cases. This alteration is
associated with high-risk disease and poor clinical outcome [1,2].
The MYCNamp plays an important role in the tumor progression. A
large number of MYCN copies correlate with invasive and meta-
static behavior of NB [3]. Furthermore, the gain of the short arm of
chromosome 2 (2p gain) also affects NB cells [4e6]. Moreover, in-
ternational guidelines for the fluorescence in situ hybridization
(FISH) examination of NB cells clearly indicate a difference between
MYCNgain and 2p gain [1]. Resent results suggest that 2p gain is not
considered the pre-status of MYCNamp [5,7]. Therefore, the main
aim in this study was to compare the expression profile of genes
engaged in human tumors metastasis in the following two groups
of NB patients: 2p gain vs. MYCNamp.
2. Materials and methods
Between October 2010 and November 2016, 60 infants diag-
nosed with NB were screened in Children University Hospital in
Krakow, Poland, for the MYCN oncogene status. The FISH test using
the N-MYC (MYCN) amplification probe set was performed on
touch-print preparations of the primary tumor tissue accordingE-mail address: katarzyna.szewczyk@uj.edu.pl.
Peer review under responsibility of Pediatric Hematology Oncology Chapter of
Indian Academy of Pediatrics.
https://doi.org/10.1016/j.phoj.2018.06.005
2468-1245/© 2018 Pediatric Hematology Oncology Chapter of Indian Academy of Pediat
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).manufacturer's protocol (Cytocell Ltd., Cambridge, UK). In addition,
another three unfavorable segmental chromosomal aberrations
1p36 deletion, 11q23 deletion, and 17q gain were studied by FISH.
About 12 in 60 (20%) children were diagnosed with MYCNamp (3
with heterogeneous form) and 11 (18%) as 2p gain (6 with het-
erogeneous form). In this study, 6 patients (3 withMYCNamp and 3
with 2p gain) were selected based on the following inclusion
criteria: alive in remission and homogeneous change of MYCN
status. The study group included 4 patients over 12th month of life,
4 with the most advanced 4th stage according International Neu-
roblastoma Staging System (INSS), and 5 having additional chro-
mosomal alterations (Table 1). Patients with NB in Children
University Hospital in Krakow are treated according the European
International Society of Pediatric Oncology Neuroblastoma Group
(SIOPEN) protocols for high-risk as well as low and intermediate
risk group.
Total RNA was extracted from deep-frozen (80 C) tumors
tissues using TRI Reagent™ Solution (Invitrogen, Thermo Fisher
Scientific, Waltham, USA). Using a spectrophotometer (NanoDrop
ND-1000; Thermo Fisher Scientific, Waltham, USA), the RNA
quantity and purity were determined by measuring UV absorption
of the sample. Using the High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Thermo Fisher Scientific, Waltham, USA),
total RNA was enzymatically converted to cDNA.
TaqMan Arrays (Applied Biosystems™, Thermo Fisher Scientific,
Waltham, USA, cat. nr. 4414098) configured for the set of genes
engaged in human tumors metastasis pathways were used for gene
expression analysis in the study group. Each 96-well plate contains
predefined assays and 4 endogenous controls (18S, GAPDH, HPRT1,
and GUSB). In each single well, 30 ng of cDNA was used. Based on
manufacturer's guidelines, the thermal profile was adopted. The
fluorescence signal detection was performed with the Applied
Biosystems 7500 Real-Time PCR System (Applied Biosystems,
Thermo Fisher Scientific, Waltham, USA). The comparative 2-DDCt
analysis method was used.
Using a two-tailed Student's t-test for independent samples
(Statistica 12, StatSoft, Poland), statistical significance was deter-
mined. A p value of <0.05 was considered statistically significant.rics. Publishing Services by Elsevier B.V. This is an open access article under the CC
Table 1
The clinical characteristics of the selected patients.
No. Age at diagnosis (months) INSS Stage MYCN status Other genetic features
1 57.43 4 2p gain Tetrasomy 2
2 5.10 1 2p gain Disomy 2
3 8.73 1 2p gain Trisomy 2
4 27.63 4 MYCNamp Tetrasomy 2, del1p36, del11q23, gain 17q
5 72.33 4 MYCNamp Tetrasomy2
6 17.23 4 MYCNamp Trisomy 2, del1p36, del11q23
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The HPRT1 gene was excluded from analysis. This gene was the
inadequate endogenous control due to the average Ct value over 30.
The average Ct values from 3 other control genes (18S, GAPDH,
GUSB) for 6 samples ranged from 21.2 to 28.8. As it was mentioned,
in one sample, the quality of RNA was low (Ct¼ 28.8), but this
sample was not excluded in view of the biological meaning of this
very small study group.
The expression level in the set of genes was mostly higher in the
MYCNamp group (average fold change¼ 2.88; range: 1.04e7.72 for
65 genes). The highest 7.72 fold change was noted for the HGF gene.
Only for 12 out of 92 genes expression level was elevated in the 2p
gain group (average fold change¼ 2.37; range: 1.03e7.83) (genes:
CTBP1, CTNNA1, DCC, EPHB2, ERBB2, FGFR4, HRAS, LAMB1, NCAM1,
PNN, PECAM, and TCF20). The very low expression level was
detected for 15 out of 92 genes: CCL7, CDH1, ETV4, KISS1, KISS1R,
LYPD3, MMP1, MMP3, MMP7, MMP10, PSCA, RET, SERPINB5, TMPRSS4,
and TSHR in both groups.
The observed differences in the expression level of selected
metastasis genes between studied groups 2p gain vs. MYCNamp
were significant for FGFR4 (p¼ 0.01) and NCAM1 (p¼ 0.04) genes.
These genes were higher transcribed in 2p gain NB tumor samples
(FGFR4 fold change¼ 4.82; NCAM1 fold change¼ 7.83).4. Discussion
The MYCNamp is one of the most powerful adverse prognostic
factors for neuroblastoma [1e3,8]. The multiplication of MYCN
oncogene copies also appears as 2p gain [4e7]. However, 2p gain
was not reported as the independent prognostic factor for neuro-
blastoma [9]. One way of activating proto-oncogenes is the repe-
tition of DNA segments. It may contribute to enhancing followed
gene expression. The clinical significance of increased expression of
MYCN remains unclear in NB [10]. In addition, it was shown that
MYCNamp may not directly affect the MYCN gene expression in NB
patients [11].
The structural chromosomal alteration like 2p gain occurs un-
expectedly common among Polish patients diagnosed with NB in
comparison to international data (18% vs. 6e18%). The meaning of
this aberration for NB biology still remains unknown. Therefore,
this group of NB patients was the key research theme. NB is the
most common solid tumor of childhood. However, the occurrence
in Poland is about 70 cases per year, and in Krakow, it is under 10
patients yearly. Consequently, the size of the study group was the
largest problem. Nevertheless, a small but very selected group of
NB patients was collected.
We reported slight differences in the expression level of genes
engaged in human tumors metastasis pathways between our
studied groups such as 2p gain vs. MYCNamp. The HGF genewas the
most overexpressed in the MYCNamp group. The HGF protein acts
as an endogenous ligand for the MET proto-oncogenic receptor of
tyrosine kinase and as an angiogenic growth factor. Previous study
showed elevated concentrations of HGF in NB patients suggestingan enhanced invasiveness and a correlation with unfavorable ge-
netic markers [12,13].
We found only two significant differences between study
groups. There distinctions were concerned with FGFR4 and NCAM1
genes whose expression was higher in the 2p gain group. The
FGFR4 plays an important role in the regulation of cell proliferation,
differentiation and migration, and lipid metabolism. Moreover,
expression of FGFR4 resulted in decreased cell adhesion. The per-
manent up-regulation of FGFR4 signaling was observed in rhab-
domyosarcoma. The FGFR4-activating mutations were also seen in
adenocarcinomas and glioblastomas. In hepatocellular carcinoma,
FGFR4 expression correlated with worse prognosis via stimulation
of hepatocyte proliferation. In astrocytomas, FGFR4 overexpression
was correlated with advanced tumor stages and short survival, as
well as prostate and thyroid cancers [14]. In colorectal cancer, the
FGFR4 gene upregulation acts as a radioresistance factor. The NB
tumor cells have been shown to express the FGFR4 ligand and FGFR
family members [15]. There is no confirmed role of the FGFR4 gene
in biology and development of the NB cancer cells, but there are
indications that it may be a potential prognostic factor. Moreover,
latest studies have shown an association between the FGFR4
polymorphism (Gly388Arg) and increased incidence of NB. This
polymorphism has been reported as an important factor in
decreasing survival rates, treatment resistance, and more aggres-
sive disease in a variety of malignancies [14,16]. Megioni et al. found
that microRNAs regulating gene expression were differentially
expressed in NB with or without MYCNamp, and these micro-
molecules were also involved in the FGFR pathway [17]. Moreover,
possible anticancer therapies were suggested based on FGFR4 in-
hibition by antibody or short hairpin (sh)RNA blocking [14].
The NCAM1 protein is a member of the immunoglobulin su-
perfamily involved in cell-to-cell and cell-matrix interactions dur-
ing development and differentiation. The NCAM1 has also been
shown to be involved in development of the nervous system. The
NCAM1 gene is widely expressed in neuroectodermal tumors such
as neuroblastoma [18]. A comparative study on the expression of
NCAM isoforms in NB tissues has indicated an association between
an isoform and tumor differentiation status and metastatic poten-
tial [19]. Moreover, NB tumor cells express polySia-NCAM that
correlates with aggressive disease and poor clinical outcome.
Therefore, enzymes engaged in polySia-NCAM biosynthesis and
NCAM protein are considered as druggable targets [20,21]. In
addition, in the mouse model of the pancreatic tumor, NCAM
formed a complex with FGFR4. This complex was required for
neurite outgrowth and cell-matrix attachment of the tumor cells.
Authors suggested that this dependency explains the metastasis
formation [14].5. Conclusions
The MYCNamp remains the most unfavorable prognostic factor
in NB. However, there is still limited knowledge about effects of the
MYCN oncogene and multiplication of its chromosomal locus 2p24
on the NB tumor cell biology. Our research sheds new light on the
K. Szewczyk / Pediatric Hematology Oncology Journal 3 (2018) 48e5050role and mechanism of 2p gain in the pathogenesis of neuroblas-
toma. We indicated two potentially important genetic factors, but
additional studies are required to confirm mentioned associations.
The study group should be enriched about new participants. The
research data about the FGFR4 expression level should be corre-
lated with the mentioned polymorphism and clinical features. The
microarray expression analysis may indicate new connection
pathways.
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